GLP1R and obesity disorder: Through its unique mechanism of action as a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, as well as its impressive results in clinical trials, tirzepatide has the potential to completely transform the current approach to treating obesity.